Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

Inclusion Criteria: * Histologically or cytologically proven squamous cell carcinoma of the head and neck or its variants (such as basaloid squamous cell carcinoma, undifferentiated carcinoma, or adenosquamous cell carcinoma). Primary tumor sites eligible include: nasopharynx, oral cavity, oropharynx, hypopharynx, larynx or unknown primary SCCHN * Stage III or IV disease, without evidence of distant metastasis, according to American Joint Committee on Cancer * Measurable disease, according to RECIST. * No prior chemotherapy, radiotherapy or attempted complete resection of the SCCHN. Diagnostic biopsy, including excisional nodal biopsy and/or tonsillectomy is allowed if the subject has measurable disease at the time of enrollment * 18 years of age or older * ECOG Performance Status of 0 or 1 * No active alcohol addiction or other condition that, in the opinion of the study investigators, would interfere with the subject's ability to comply with the treatment plan * Adequate hepatic and renal function * Women of childbearing potential must have a negative pregnancy test within 2 weeks of study entry. Exclusion Criteria: * Pregnant or breast feeding women * Symptomatic peripheral neuropathy of grade 2 or higher by NCI CTCAEv3.0 * Grade 3 or more hearing loss * History of other malignancy within the previous 5 years, except for nonmelanoma skin cancer, carcinoma in situ of the cervix, bladder or head and neck * Prior radiation to head and neck * Other serious illness or medica…